Author: Neil Canavan

Research oncologists are not given to hyperbole, so when the words, “extraordinary” and “unprecedented” are used during a scientific presentation you need to pay attention.

Once again, a drug that enhances a patient’s own immune system has shown a marked improvement in tumour regression as compared to standard chemotherapy regimens in the treatment of advanced melanoma.

It is hard to deny the power of heavy metal – not so much Metallica but X-ray-enhancing nanoparticles made of hafnium.

The combined use of two new agents that boost the immune system has demonstrated an unprecedented improvement in tumour regression and overall survival for patients with advanced melanoma.

Pharmacyclics and Johnson & Johnson’s ibrutinib has caused a stir at the American Society of Clinical Oncology meeting in Chicago, with many observers predicting that it will revolutionise treatment of chronic lymphocytic leukaemia.